Non ischaemic preservation of the donor heart in japanese, non ischaemic preservation of the donor cast, non ischaemic preservation of life, non ischaemic preservation of the donor heart in french, non ischaemic preservation of the donor in the drink, non ischaemic preservation of the donor heart infection, non ischemic preservation windows, non ischaemic preservation of the donner party, non ischaemic preservation of food, non ischaemic preservation of the donor movie, non ischaemic preservation of the donor heart institute, non ischaemic preservation of the donor heart inflammation, non ischaemic preservation of the donor heart in concert, non ischemic preservation distillery, non ischaemic preservation of the saints, non ischaemic preservation of natural resources, non ischaemic preservation of capital.
Non-ischaemic preservation of the donor heart in heart transplantation: protocol design and rationale for a randomised, controlled, multicentre cli nical trial across eight European countries.
Abstract
Ischaemic cold static storage (ICSS) is the gold standard in donor heart preservation. This ischaemic time frame renders a time constraint and risk for primary graft dysfunction. Cold oxygenated heart perfusion, known as non-ischaemic heart preservation (NIHP), theoretically limits the ischaemic time, while holding on to the known advantage of hypothermia and cardioplegia, a low metabolic rate. The NIHP 2019 study is an international, randomised, controlled, open, multicentre clinical trial in 15 heart transplantation centres in 8 European countries and includes 202 patients undergoing heart transplantation, allocated 1:1 to NIHP or ICSS. Enrolment is estimated to be 30 months after study initiation. The patients are followed for 12 months after transplantation.The primary objective is to evaluate the effect of NIHP on survival, allograft function and rejection episodes within the first 30 days after transplantation. The secondary objectives are to compare treatment groups with respect to survival, allograft function, cardiac biomarkers, rejection episodes, allograft vasculopathy, adverse events and adverse device effects within 12 months. This protocol was approved by the Ethics Committee (EC) for Research UZ/KU Leuven, Belgium, the coordinating EC in Germany (Bei Der LMU München), the coordinating EC in the UK (West Midlands-South Birmingham Research), the EC of Hospital Puerta de Hierro, Madrid, Spain, the EC of Göteborg, Sweden, the coordinating EC in France, the EC of Padova, Italy and the EC of the University of Vienna, Austria. This study will be conducted in accordance with current local regulations and international applicable regulatory requirements according to the principles of the Declaration of Helsinki and ISO14155:2020. Main primary and secondary outcomes will be published on modified intention-to-treat population and per-protocol population. NCT03991923.
Authors (4) : Janne Brouckaert, Göran Dellgren, Andreas Wallinder, Filip Rega
Source : BMJ open
Article Information
| Year | 2023 |
| Type | Journal Article |
| DOI | 10.1136/bmjopen-2023-073729 |
| ISSN | 2044-6055 |
| Volume | 13 |
You can download journal here :
If You have any problem, contact us here
